97 treatment with ramipril reduced cardiovascular events and mortality even in patients without
hypertension. Therefore, ramipril should be considered as a
ﬁrst-line choice for hypertension treatment in PAD patients,
although it should be used with caution in the presence of
renal artery stenosis. In a recent double-blind, placebocontrolled RCT, ramipril (10 mg/d for 24 weeks) was
associated with signiﬁcant improvements in pain-free and
